Perrigo Loratadine 10 Mg 505(b)(2) Should Be Denied – Genpharm Petition
This article was originally published in The Tan Sheet
Executive Summary
FDA should "send a prompt letter ruling" to Perrigo denying approval of the firm's 505(b)(2) application for 10 mg loratadine tablets, according to an April 15 citizen petition submitted to the agency by Genpharm
You may also be interested in...
Schering Plans For Possible Clarinex Switch By Readying OTC Division
Preparations for a possible Rx-to-OTC switch of Clarinex (desloratadine) will be directed by Schering Consumer Health Care Division Chairman Stanley Barshay
Schering Taps Former AHP Exec Barshay To Head Consumer Health Care Unit
Schering-Plough appointed former American Home Products Senior VP Stanley Barshay as chairman of its Consumer Health Care division effective July 7
Perrigo’s Loratadine 505(b)(2) NDA Was Properly Submitted, Firm Maintains
Perrigo chose to file a 505(b)(2) NDA for its generic loratadine 10 mg tablet because at the time it submitted the application, reference listed drug Claritin still was a prescription product, the firm states in recent comments to FDA